Review articleEpigenetics and immunotherapy: The current state of play
Under a Creative Commons license
open access
Abbreviations
TME
tumour microenvironment
PD-1
programmed cell death 1
PD-L1
programmed death ligand 1
PD-L2
programmed death ligand 2
PTMs
post-translational histone modifications
DNMTi
DNA methyltransferase inhibitor
HDACi
histone deacetylase inhibitor
TAA
tumour-associated antigens
APM
antigen processing and presentation machinery
NK
natural killer
NKG2D
NK group 2D
MICA/B
MHC class I-related chain A/B
ULBPs
ULB16-binding proteins
TRAIL
TNF-related-apoptosis inducing ligand
FASL
FAS ligand
DC
dendritic cell
APC
antigen presenting cells
TFH
T follicular helper
Treg
regulatory T cell
CTL
cytotoxic T lymphocyte
TCR
T cell receptor
HLA
human leukocyte antigen
TAP
transporter associated with antigen presenting
ICAM-1
intercellular adhesion molecule 1
TILs
tumour-infiltrating lymphocytes
CTLA-4
cytotoxic T lymphocyte antigen 4
TNBC
:triple-negative breast cancer
NSCLC
non-small cell lung cancer
AML
acute myeloid leukaemia
CCL
chronic lymphatic leukaemia
mAb
monoclonal antibody
FDA
Food and Drug administration
Ig
immunoglobin
PI3K
phosphoinositide 3-kinase
MDSC
myeloid-derived suppressor cell
CAF
cancer-associated fibroblast
CSC
cancer stem cell
HGF
hepatocyte grown factor
CTAs
cancer testis antigens
HMW-MAA
high molecular weight melanoma-associated protein
Th1
T helper 1
EZH2
enhancer of zeste homologue 2
H3K27
me3: histone 3 lysing 27 trimethylation
DNMT1
DNA methyltransferase 1
ERVs
endogenous retroviral sequences
5-AZA-dC
5-aza-2′-deoxycytidine
Keywords
Epigenetics
Immunotherapy
Immune checkpoint blockade
Combination therapy
DNA methyltransferase inhibitors
Histone deacetylase inhibitors
Cited by (0)
© 2017 The Authors. Published by Elsevier Ltd.